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Background: Chlamydia is a common bacterial pathogen responsible for many diseases. Methods for transforming
this important organism using a β-lactamase as a selection marker have been developed very recently. However,
the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules do not permit
transformation experiments with β-lactamase gene-containing vectors for certain human chlamydial pathogens.
Therefore, a different selection marker is urgently needed for transformation of those chlamydiae.
Results: After transformation of plasmid-free Chlamydia trachomatis with pGFP:SW2, which carries a β-lactamase
and a chloramphenicol acetyltransferase gene fused to a green fluorescence protein gene, transformants were
obtained by selection with either ampicillin or chloramphenicol. Stable chloramphenicol-resistant, but ampicillin-
sensitive, transformants were obtained using a pGFP:SW2 derivative without the β-lactamase. All transformants
expressed green fluorescence protein and had glycogen synthesis activity restored.
Conclusions: Chloramphenicol resistance may be used as a selection marker for genetic experiments in Chlamydia.
This eliminates the requirement for the use of β-lactamase, of which dissemination to some C. trachomatis serovars
may jeopardize clinical treatment of chlamydial infections in pregnant women. Chloramphenicol acetyltransferase
may also serve as a useful secondary selection marker for genetic analyses in β-lactamase-transformed chlamydial
strains.
Keywords: Chlamydia, Chlamydia trachomatis, Chloramphenicol, Chloramphenicol acetyltransferase, Sexually
transmitted infections, Transformation, Transformation selection markerBackground
Chlamydia is a bacterium that replicates only inside a
eukaryotic host cell, and is a causative agent for a
number of human diseases [1,2]. Acquired by sexual
transmission, replication of Chlamydia trachomatis at
the lower genital tract causes cervicitis [1]. Subsequently,
chlamydiae ascend to the upper genital tract, causing
inflammation leading to tissue disruption and scarring in
the uterus and oviducts. Inflammation in the uterus dur-
ing pregnancy may lead to abortion and premature birth,
whereas chlamydial oviductal pathology constitutes the
number one cause of female infertility, and ectopic preg-
nancy [1]. Furthermore, an infant of an infected mother
may acquire the pathogen while passing the birth canal,
and develop respiratory infection [1]. C. pneumonia is a* Correspondence: huizhou.fan@rutgers.edu
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reproduction in any medium, provided the orcommon pathogen of community-acquired respiratory
infection, and a co-factor for arteriosclerosis and late-
onset Alzheimer disease [3-5]. At the present time, no
vaccine effective against human chlamydial diseases or
other preventive means are available [6,7].
Chlamydia has a unique developmental cycle, which
consists of two alternating cellular forms: the infectious
but non-dividing elementary body (EB) and the dividing
but non-infectious reticulate body (RB). Developmental
events including conversion of EB to RB, replication of
RBs, and RB to EB reorganization take place inside a
cytoplasm vacuole designated inclusion. For a long
period of time, study of Chlamydia has been severely
hampered by a lack of a convenient genetic system.
Fortunately, a method for transforming C. trachomatis
with shuttle vectors using CaCl2 has been developed very
recently by Wang et al. [8], and has been adopted by others
[9,10]. Furthermore, Gérard et al. have transformed C.
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lactamase, which degrades penicillin family antibiotics, and
thus relieves their inhibitory effects of these drugs on the
cytokinesis of RBs [8,9]. Since amoxicillin, a penicillin fam-
ily member, is recommended for treatment of chlamydial
cervicitis in pregnant women, transformation experiments
using β-lactamase marker for sexually transmitted, non-
LGV chlamydial pathogens (i.e., C. trachomatis serovar D
to K), are not permitted by the National Institutes of Health
Guidelines for Research Involving Recombinant DNA Mol-
ecules. Therefore, there is an urgent need to identify selec-
tion markers for recombination studies in those chlamydial
serovars. In addition, there is also a need to identify second-
ary selection markers for chlamydiae which may already
carry an established resistant marker such as a β-lactamase
for different reasons in future studies. Here, we report the
identification of a chloramphenicol acetyltransferase (CAT)
gene as a useful selection marker.
Methods
Tissue culture and molecular biology reagents
Dulbecco’s modified Eagle’s medium (DMEM) with high
glucose (4.5 g/L) and 110 mg/L sodium pyruvate, fetal bo-
vine serum (FBS), Dulbecco’s phosphate-buffered saline
(PBS), trypsin-EDTA solution for cell culture, Trizma base,
cycloheximide, CaCl2, ampicillin, chloramphenicol and
Lugol solution were purchased from Sigma Aldrich.
Gentamycin and transformation-competent Escherichia coli
stbl2 cells were purchased from Invitrogen. Pfu Ultra DNA
polymerase was purchased from Agilent. BamH1 and the
Q5 Site-Directed Mutagenesis Kit were purchased from
New England Biolabs.
Vectors
pGFP::SW2 is a shuttle vector containing an E. coli repli-
cation origin, a β-lactamase gene, a chloramphenicol
acetyltransferase gene fused to DNA coding for a
red-shifted green fluorescence protein (GFP), and nearly
the complete sequence of a C. trachomatis plasmid
designated SW2 (Figure 1, top) [8]. pGFP-CAT::SW2
(Figure 1, bottom) was derived by deletion of the β-
lactamase gene from pGFP::SW2. Briefly, the 7169 bp
SW2 DNA was removed from the plasmid by first amp-
lifying the non-chlamydial DNA sequence using the Pfu
Ultra DNA polymerase and a pair of mutually comple-
mentary primers, GFP-5’c (5’TAGATTAATGTCGACTC
TAGAGGATCCGGGTACCGAGCTCGAA3’) and GFP-
3’c (5’TTCGAGCTCGGTACCCGGATCCTCTAGAGTC
GACATTAATCTA3’), which target the termini of the
non-chlamydial DNA fragments, and then circularization
of the fragment in E. coli. Likewise, the BamH1 site within
the GFP coding sequence of the resulting 4,370 bp plasmid,
designated pBETA-GFP-CAT, was inactivated using the
mutually complementary primers GFP-Del-BamH1-5’c(5’AAGCCGATATGGTGGATTCCCGGGTACCAATGA3’)
and GFP-Del-BamH1-3’c (5’TCATTGGTACCCGGGAAT
CCACCATATCGGCTT3’). The 861 bp β-lactamase open
reading frame was removed from the plasmid using the
Q5 Site Directed Mutagenesis Kit to yield the plasmid
pGFP-CAT. Primers for Q5-mediated mutagenesis were
Del-amp1 (5’CTGTCAGACCAAGTTTAC3’) and Del-
amp2 (5’ACTCTTCCTTTTTCAATATTATTG3’). Fi-
nally, the 7168 bp SW2 fragment was inserted to the
BamH1 site of the pGFP-CAT to yield pGFP-CAT:
SW2 (Figure 1). Chloramphenicol was used to select E.
coli transformed with pGFP-CAT and pGFP-CAT:SW2
(Figure 1). Sequence authenticity of the SW2 portion
of pGFP-CAT::SW2 was confirmed through paid ser-
vice provided by Macrogen USA.Plasmid DNA preparation
E. coli stbl2 cells were used to grow plasmids. Plasmid
DNA was purified using Qiagen Midi DNA purification
columns, precipitated by ethanol and redissolved in 10
mM Tris-HCl (pH 8.5). DNA concentration of final
preparations was 2.5 μg/μl or above.Cells and culture conditions
HeLa and McCoy cells were purchased from American
Type Culture Collections (ATCC, Manassas, VA), and
maintained as adherent cultures in 5% CO2 incubators with
100% humidity using DMEM containing 10% FBS [8].Preparation of EBs for transformation
EBs for transformation experiments were prepared as previ-
ously described [8] with minor modification. Five T150
flasks of 95% confluent HeLa cells were inoculated with an
EB stock of the plasmid-free C. trachomatis 2566R (L2R)
[12] at a multiplicity of ~5 inclusion-forming units (IFU)
per cell, and cultured with medium containing 20 μg/ml
gentamycin and 1 μg/ml cycloheximide. 46 h after inocula-
tion, the infected monolayers in each flask were briefly
rinsed with 5 ml PBS, and 3 ml of trypsin-EDTA. When
cells appeared to have rounded up under an inverted
microscope, they were collected into 8 ml DMEM-FBS.
Cells from all 5 flasks were pooled, and subjected to centri-
fugation at 500 g for 10 min. Following the removal of the
supernatant, cells were resuspended in 1 ml SPG buffer
[13] and disrupted by three cycles of 5-s on/5-s off sonic-
ation using a Sonic Ultrasonic Processor (Model number:
GEX 130) equipped with a 3-mm diameter stepped
microtip. The energy intensity level of the sonicator was set
at 40% [14]. The cell lysate was centrifuged at 750g for 10
min. Aliquots of the supernatant, which contained EBs,
were made and stored at -80°C. The titer of this batch of
EB stock was determined to be 2 × 109 IFU/ml.
Figure 1 Schematic presentation of pGFP::SW2 (top) [8] and its derivative pGFP-CAT::SW2 (bottom). Sequence originated from the C. trachomatis
SW2 plasmid is shown in red, and non-chlamydial sequences in black. Compared to pGFP::SW2, the β-lactamase gene has been removed and a BamH1
cutting site located upstream of the GFP-CAT fusion gene has been inactivated in pGFP-CAT::SW2. All other features, including the C. trachomatis plasmid
replication origin (pSW2 ori) and coding sequences (CDS) 1-8, E. coli pUC replication origin (pUC ori), the GFP-CAT fusion gene and the Neisseria
meningitidis promoter (nmP) that drives the expression of GFP-CAT, remain unchanged in pGFP-CAT::SW2. See Methods for construction details.
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Transformation was carried out as previously described
[8] with modifications. 7.5 μl of the above frozen L2R EBstock was combined with 10 μg plasmid DNA in 3.5 μl
volume and 189 μl 50 mM CaCl2 buffer (prepared with
10 mM Tris, pH 7.4) in a 1.5 ml tube, which was let
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20 h culture at 80% confluence in a 145-mm diameter plate
were trypsinized, collected into 14 ml antibiotic-free
DMEM-FBS, and centrifuged at 500 g for 5 min. Following
the removal of the supernatant, the cell pellet was rinsed
gently with 10 ml of PBS, resuspended with 14 ml PBS, and
centrifuged again. The pellet was resuspended in 220 μl
CaCl2 buffer. 200 μl of the cell suspension was then added
into the plasmid-EB-CaCl2 mix. The final transformation
mix was incubated at room temperature for 20 min, during
which the tube was shaken from time to time to prevent
settling of the cells. At the end of the 20 min incubation
period, the cells were diluted with 20 ml DMEM-FBS, and
plated onto four T25 flasks (5 ml/flask) and were cultured
at 37°C under 5% CO2 and 100% humidity.
Selection of transformants was initiated 10 h after the ini-
tial plating of the transformation. Ampicillin and chloram-
phenicol were added to the cultures to yield a final
concentration of 2 μg/ml and 0.1 μg/ml, respectively. This
initial passage was defined as passage 1. 46 h later, cells in
the T25 flasks were harvested and disrupted by sonication.
The entirety of the P1 culture was passed onto a new T25
flask of McCoy cells at 80-90% confluence. The P2 flasks
were cultured with DMEM-FBS containing 1 μg/ml cyclo-
heximide plus 5 μg/ml ampicillin or 0.2 μg/ml chloram-
phenicol. Passage and selection were repeated every 48 h
for two additional passages through passage 4. 90% harvest
of passage 4 was frozen and the remaining was expanded
with medium containing 5 μg/ml ampicillin or 0.5 μg/ml
chloramphenicol.
Glycogen stain
To stain glycogen in chlamydial inclusions, the culture
medium was replaced with Lugol solution, which con-
tains iodine, at 40 h after inoculation.
Imaging acquisition and processing
All phase contrast and GFP images were obtained at 40 h
post inoculation from live cultures in PBS supplemented
with 1.3 mM CaCl2, 1.0 mM MgCl2 and 1.0 g/L (w/v) glu-
cose using an Olympus IX-51 microscope and an Olympus
monochrome CCD camera. Images processing (coloring
and color overlay) were accomplished by using the Picture
Frame software [15,16].
Results and discussion
pGFP::SW2, the shuttle vector constructed by Wang et al,
contained a β-lactamase gene as a selection marker. It also
carries a CAT gene that is fused to the GFP gene [8]. We
found that E. coli transformed with the pGFP::SW2 plas-
mid was able to grow in medium containing chloram-
phenicol (final concentration: 170 μg/ml), suggesting
that the CAT gene may also be used as a selection markerfor chlamydial transformation experiments. As cautioned
by Wang et al., an adverse effect of chloramphenicol on
host mitochondria, as demonstrated by Li et al. [17]
may affect the utility of this antibiotic for chlamydial
transformation [8]. In Li et al.’s report, the minimal toxic
concentration of chloramphenicol was 10 μg/ml, which
caused a mild 20% reduction of ATP production. We have
determined that the apparent lowest chloramphenicol
concentration that completely inhibited inclusion formation
in the plasmid-free C. trachomatis L2 strain designated L2R
was only 0.05 μg/ml (data not shown), which was far
below the concentrations toxic to host cells. Therefore, we
reasoned that this antibiotic could be used to select CAT-
expressing transformants without significantly stressing
host cells.
We transformed L2R with pGFP::SW2, and selected one
half of the transformed cells with ampicillin, and the other
half with chloramphenicol. The antibiotics (2 μg/ml ampi-
cillin or 0.1 μg/ml chloramphenicol) were added to the cul-
tures at 10 h after transformation. Starting at passage 2,
their concentrations were increased to 5 and 0.2 μg/ml, re-
spectively, and they were added at the time of inoculation.
The splitting ratio between passages remained 1:1 from
passage 1 though passage 4. Even though the MIC of
chloramphenicol, which was determined at low multiplicity
of infection (~0.1 inclusion-forming units per cell), was
0.05 μg/ml, some of the untransformed chlamydiae were
expected to form inclusions in the presence of 0.1 - 0.2 μg/
ml the antibiotic, because we used a high EB to cell ratio
for transformation, and efficacy of chlamydial growth
inhibition by antibiotics is influenced by the multipli-
city of infection [18]. With the above described selec-
tion protocol, in cultures selected with ampicillin,
under a phase-contrast microscope, nearly 100% cells
were found to contain an inclusion with aberrant RBs
at the initial passage. The aberrant RB-containing in-
clusions were still present in a small proportion of cells
at passage 2, but were mostly replaced by apparently
normal inclusions at passage 3. Normal inclusions were
found in about 20% cells, and abnormal inclusions were
rarely observed at passage 4. At passage 5, which
resulted from inoculation with 10% harvest from pas-
sage 4, inclusions were found in 80% cells; apparently,
none of these inclusions contained aberrant RBs.
Since chloramphenicol does not cause chlamydiae to
form aberrant RBs, we judged resistance to the antibiotic
by the inclusion size. Inclusions of smaller-than-normal
sizes were detected in almost all cells at passage 1. Some,
but very small-sized, inclusions were found at passage
2, and most of those inclusions were replaced with normal-
sized inclusions by passage 3. Normal-sized inclusions were
found in more than 20% cells at passage 4. At passage 5,
derived after inoculation with 10% passage 4 harvest, and an
increase in chloramphenicol concentration (from 0.2 μg/ml
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100% cells 0000000.
In addition to apparent resistance to the selection agents,
we used GFP expression and restoration of glycogen syn-
thesis as additional markers for successful transformation
[8,9,19]. EBs harvested from passage 5 were used to infect
McCoy cells at a 1:100 dilution rate (cell number equiva-



































Figure 2 Inclusion, GFP expression and glycogen synthesis of pGFP::SW2
strain 434/bu (A), untranformed plasmid-free strain L2R (B-D), and transformed
(F, H) were cultured either with medium containing an indicated antibiotic or w
stained cultures were acquired with phase contrast microscopy or fluorescence
images are superimposable.glycogen synthesis (Figure 2). As expected, neither wild-
type plasmid-replete C. trachomatis L2 (434/bu) (Figure 2A)
nor untransformed plasmid-free L2R (Figure 2B) expressed
GFP. Consistent with established findings that glycogen
synthesis in C. trachomatis requires its plasmid [8,9,19,20],
iodine stain showed that glycogen was accumulated in the
inclusions of wild-type L2 (Figure 2A) but not those of L2R
(Figure 2B). In the presence of 5 μg/ml ampicillin, whichGlycogenrast GFP
transformants of C. trachomatis L2. Untransformed plasmid-replete
L2R selected with either ampicillin (E, G) or chloramphenicol
ith antibiotic-free medium. Images of inclusions in unstained and iodine-
microscopy 48 h post-inoculation. In all panels, phase contrast and GFP
Xu et al. BMC Research Notes 2013, 6:377 Page 6 of 7
http://www.biomedcentral.com/1756-0500/6/377inhibits RB division, non-transformed L2R (Figure 2C)
formed inclusions containing giant RBs without producing
glycogen; whereas chloramphenicol (final concentration:
0.5 μg/ml) completely inhibited the formation of visible in-
clusions in L2R infected-cells (Figure 2D). Consistent with
data published by Wang et al. [8], pGFP::SW2-transformed
L2R selected with ampicillin formed GFP-positive inclu-
sions with glycogen (Figure 2E). pGFP::SW2-transformed
L2R selected with chloramphenicol also formed GFP-
positive inclusions containing glycogen (Figure 2F). As
expected, ampicillin-selected transformants were able to
form normal-sized, GFP-positive, glycogen-containing in-
clusions in the presence of chloramphenicol (Figure 2G);
likewise, chloramphenicol-selected transformants were
completely resistant to ampicillin, expressed GFP and pro-
duced glycogen (Figure 2H). These results suggest that the
CAT gene in the pGFP::SW2 plasmid is functional in chla-
mydiae, and chloramphenicol-resistance can be used as a
selection marker for chlamydial transformation.
We next removed the β-lactamase gene from the
pGFP::SW2 plasmid as described in the “Methods” sec-
tion, and used the resulting pGFP-CAT::SW2 plasmid to
transform L2R. Transformed chlamydiae were subjected
to selection with chloramphenicol using the same regi-
men as described above. Chloramphenicol-resistant in-
clusions emerged in about 20% of the infected cells in
the culture of passage 4. Fluorescence microscopy and
iodine stain revealed GFP- and glycogen-positive inclu-
sions in cells that were infected with EBs harvested from
passage 5, and cultured in the presence of chloram-
phenicol (Figure 3, upper panel). However, as a result of
a lack of β-lactamase in the pGFP-CAT::SW2 plasmid,
the transformants were not able to form normal inclu-
sions in the presence of ampicillin; instead, their inclu-
sions were filled with aberrant RBs. While the irregular
inclusions were still positive for GFP, they were largely
free of glycogen (Figure 3, lower panel). After passage 5,CAM
AMP
Phase contrast
Figure 3 Inclusion, GFP expression and glycogen synthesis in L2R tran
selected transformants were exposed to either chloramphenicol or ampicil
acquired with phase contrast microscopy or fluorescence microscopy 48 hthe pGFP-CAT::SW2 transformants were cultured with
0.5 μg/ml chloramphenicol for additional four passages
at a 1:100 splitting ratio for each passage. All inclusions
at passage 9 had the same appearance as the inclusions
of plasmid-replete chlamydiae and not that of the
plasmid-free L2R, and all were found to express GFP
(data not shown). These results prove that the CAT gene
in the pGFP-CAT::SW2 plasmid, similar to the pGFP::
SW2 plasmid, functions as a selection marker for C.
trachomatis transformation.
It should be noted that Tam et al. has previously
attempted to develop a transformation system with the
CAT gene as a selective marker [21]. In that study, a
shuttle vector containing a CAT gene was electroporated
into EBs of C. trachomatis E (strain UW-5/CX) and L2
(strain 434/Bu). Although both CAT mRNA and enzyme
activity were detectable in the initial cultures of
transformed chlamydiae, the authors failed to obtain
stable transformants after selection with chlorampheni-
col for 4 passages. It is important to note that both
strains electroporated contain a native plasmid that
shares the same replication origin with the recombinant
plasmid used for transformation [21]. Since Wang et al.
were able to obtain stable penicillin-resistant transformants
only from L2R, a plasmid-free C. trachomatis L2 variant,
but not the wild-type, plasmid-replete 434/Bu, under other-
wise identical experimental settings [8], it is retrospectively
not surprising that Tam et al. failed to derive stable
chloramphenicol-resistant chlamydiae.
Conclusions
We have shown that for the plasmid-free C. trachomatis
L2R, chloramphenicol can be used to select transformants
when a shuttle vector that carries a CATgene is used. Since
Wang et al in Europe were able to select transformants of a
clinical strain of serovar F with penicillin [19], CAT gene
should be a highly useful and legally compatible selectionGFP Glycogen
sformed with pGFP-CAT::SW2. Cells infected with chloramphenicol-
lin. Images of inclusions in unstained and iodine-stained cultures were
post-inoculation. Phase contrast and GFP images are superimposable.
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which use of β-lactamase-carrying vectors are currently not
permitted in the US. Furthermore, we envision that the
CAT gene may also serve as a valuable secondary marker
for conducting gene-targeting experiments and other gen-
etic experiments such as in C. trachomatis lymphogranu-
loma strains that (will) have already been transformed with
a β-lactamase-bearing plasmid.
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